Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Book value per share
Solventum Corporation's book value per share at the end of fiscal 2025 was 29.0×, up 69.8% from 17.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 27.8×. Solventum Corporation ranks 15th of 56 Medical Instruments & Supplies companies by book value per share.
Book value per share, annual
Annual
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 29.0× | 69.75% |
| FY2024 | 17.1× | (74.71%) |
| FY2023 | 67.6× | — |
| FY2022 | 0.0× | — |
Quarterly
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 27.8× | (2.56%) |
| Mar 2026 | 28.5× | (1.64%) |
| Dec 2025 | 29.0× | 1.38% |
| Sep 2025 | 28.6× | 36.63% |
| 11 more quarters | Free account |
Book value per share against peers
| Company | Book value per share |
|---|---|
| ALGN Align Technology, Inc. compare | 59.2× |
| ALC Alcon compare | 44.4× |
| COO The Cooper Companies, Inc. compare | 43.2× |
| WST West Pharmaceutical Services, Inc. compare | 42.2× |
| ATR AptarGroup, Inc. compare | 41.6× |
| RGEN Repligen Corporation compare | 37.4× |
| SOLV Solventum Corporation | 27.8× |
| BAX Baxter International Inc. compare | 12.0× |
| AVTR Avantor, Inc. compare | 8.3× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Revenue growth
- The full statement